The model was challenged to blindly predict the extrapyramidal symptoms liability of 1,124 patients prescribed two antipsychotics for six or more months (772 unique combinations). Anonymized data were derived from South London and Maudsley NHS Foundation Trust (SLAM) electronic health records (EHR). Extrapyramidal side effects were captured and identified using a combination of Natural Language Processing and a bespoke algorithm [2]. Only names and doses of the two drugs were made available without any calibration set. Results: Blind prediction of the outcomes using a Receiver Operating Characteristic curve with the QSP model resulted in an Area-Under-the Curve of 0.64 (p<0.01), compared to an AUC of 0.52 for the sum of the chlorpromazine equivalents, 0.53 for the sum of affinity constants or the sum of D2R occupancies of the individual antipsychotics (AUC=0.52). Discussion: QSP is a powerful approach to predict PD-PD interactions in the absence of any calibration set or with limited and unique data and is superior to chlorpromazine equivalents for predicting EPS liability. A major application is the simulation of pharmacodynamic interactions of comedications in clinical trials with novel compounds leading to possible better balance between the different treatment arms
The model was challenged to blindly predict the extrapyramidal symptoms liability of 1,124 patients prescribed two antipsychotics for six or more months (772 unique combinations). Anonymized data were derived from South London and Maudsley NHS Foundation Trust (SLAM) electronic health records (EHR). Extrapyramidal side effects were captured and identified using a combination of Natural Language Processing and a bespoke algorithm [2] . Only names and doses of the two drugs were made available without any calibration set. Results: Blind prediction of the outcomes using a Receiver Operating Characteristic curve with the QSP model resulted in an Area-Under-the Curve of 0.64 (p<0.01), compared to an AUC of 0.52 for the sum of the chlorpromazine equivalents, 0.53 for the sum of affinity constants or the sum of D2R occupancies of the individual antipsychotics (AUC=0.52). Discussion: QSP is a powerful approach to predict PD-PD interactions in the absence of any calibration set or with limited and unique data and is superior to chlorpromazine equivalents for predicting EPS liability. A major application is the simulation of pharmacodynamic interactions of comedications in clinical trials with novel compounds leading to possible better balance between the different treatment arms Background: Antipsychotics (APs), antidepressants (ADs) and mood stabilizers are essential components in treatment of most psychiatric disorders and in particular in schizophrenia. Unfortunately, among the various compounds which have been developed, lengthy trials are often required before the optimum medication treatment is found, i.e. with most significant symptom alleviation and minimal side effects. Thus, predictive factors would thus be extremely beneficial in clinical practice. The underlying reasons for this large inter-individual variability in terms of treatment response are not fully understood. Important factors that influence drug dose, response and side effects include age, gender, patient compliance, constellation of symptoms, co-morbidity, and to a large extent genetic factors. Methods: Methods follow two strategic concepts, i.e. 1) review of the literature and review of the clinical utility of using genetic information preemptively and 2) results of own studies evaluating treatment outcome in psychiatric care after genetic information (e.g., CYP2D6 and CYP2C19) was provided to more than 350 physicians. Results: There is growing consensus among expert that genetic testing to optimize medication treatment in psychiatry meets criteria for clinical utility. However, utility remains restricted to specific gene-drug pairs and multi-gene test require further validation. Our own research has shown that variation in genes involved in the metabolism of psychotropic drugs (pharmacokinetics) and genes encoding drug targets, such as brain receptors (pharmacodynamics) are associated with plasma drug levels, treatment response, and side effects (e.g., antipsychoticinduced weight gain). In addition, our genome-wide analyses have revealed associations with clinical outcome to antipsychotics or antidepressants and markers in neurotrophins, cell-signaling and inflammatory pathways. With respect to our preemptive genetic testing program in more than 10,000 patients, we received supportive responses from physicians who enrolled patients in our study. Notably, while the vast majority of patients reported improvement in patient outcome, only two physicians indicated that their patient's symptoms has slightly worsened after they had used the pharmacogenetic report to guide treatment. Discussion: There is emerging evidence that preemptive genetic testing for numerous gene & psychiatric-drug pairs has reached levels for clinical utility which includes validation of analytical and clinical validity.
Genetic testing has become readily available but however clinicians and patients are poorly prepared to this new emerging field and proper education is of utmost importance. This presentation will review the level of evidence for 'actionable' gene-drug pairs in psychiatry in addition to present novel genomic findings and reports from our ongoing genetic testing experiences. Background: Activation of indirect pathway medium spiny neurons (MSNs) via promotion of cAMP production is the principal mechanism of action (MOA) of current antipsychotics with dopamine D2 receptor antagonism. Phosphodiesterase 10A (PDE10A) inhibitors activate both direct and indirect pathway MSNs by increasing both cAMP and cGMP levels by inhibiting their degradation, which might be expected to promote activation of intracellular signaling similar to that of D2 antagonists in the indirect pathway MSNs. Thus, the activation of the indirect MSN pathway through the distinct MOA of these compounds raises the possibility of augmented pharmacologic effects with combined treatment.
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In this study, we compared gene-regulation patterns in the indirect pathway MSNs induced by the PDE10A inhibitors T-773 and T-609, and the D2 antagonist haloperidol, using a cell-type-specific comprehensive gene expression analysis in Drd2-bacTRAP (translating ribosome affinity purification) mice. The pharmacologic effects of combined treatment with another PDE10A inhibitor, TAK-063, and clinically used antipsychotics, haloperidol (HAL) and olanzapine (OLA), were evaluated in multiple rodent models. Methods: Male ICR mice, Drd2-bacTRAP mice, and Sprague-Dawley rats were used. The indirect pathway MSN-specific gene expression changes by T-773, T-609, and HAL were investigated using RNA sequencing of striatal samples of Drd2-bacTRAP mice. The activation of MSNs in rats was evaluated by measuring glutamate receptor subunit 1 phosphorylation (pGluR1) levels. An in vitro electrophysiological study on the corticostrial pathway in rats was conducted in a slice preparation. The activation of each MSN pathway was assessed by inducing genes as pathway-specific markers: enkephalin for the indirect pathway and substance P for the direct pathway. Suppression of MK-801-or methamphetamine (METH)-induced hyperactivity was assessed by measuring locomotor activity for 2 hours after administration of these stimulants to rats. Improvement of prepulse inhibition (PPI) was investigated in a MK-801-induced PPI deficit mouse model. Results: Translational profiling in Drd2-bacTRAP mice treated with the PDE10A selective inhibitors, T-773 and T-609, and with HAL suggested regulatory of a largely overlapping signaling pathway by these compounds in the indirect pathway MSNs: 87% of the genes regulated by HAL were also regulated by both T-773 and T-609. Combined treatment with TAK-063 and either HAL or OLA produced an augmented effect on pGluR1 in the rat striatum. An electrophysiological study in rat brain slices indicated that TAK-063 enhanced synaptic responses to a similar extent in both direct and indirect pathway MSNs. Additional evaluation using MSN pathway-specific markers revealed that coadministration of TAK-063 with HAL or OLA additively activated the indirect pathway, but not the direct pathway. Background: Cannabis use can induce acute and long-lasting psychosis and cognitive dysfunction. Some evidence suggests that the acute behavioral and neurocognitive effects of the main active ingredient in cannabis, (−)-trans-Δ9-tetrahydrocannabinol (∆9-THC), might be modulated by previous cannabis exposure. However, this has not been investigated either using a control group of non-users, or following abstinence in modest cannabis users, who represent the majority of recreational users. Methods: Twenty-four healthy men participated in a double-blind, randomized, placebo-controlled, repeated-measures, within-subject, ∆9-THC challenge study.
Results: Compared to non-users (N=12; <5 lifetime cannabis joints smoked), abstinent modest cannabis users (N=12; 24.5 ± 9 lifetime cannabis joints smoked) showed worse performance and stronger right hemispheric activation during cognitive processing, independent of the acute challenge (all P≤0.047). Acute ∆9-THC administration produced transient anxiety and psychotomimetic symptoms (all P≤0.02), the latter being greater in non-users compared to users (P=0.040). Non-users under placebo (control group) activated specific brain areas to perform the tasks, while deactivating others. An opposite pattern was found under acute (∆9-THC challenge in non-users) as well as residual (cannabis users under placebo) effect of ∆9-THC. Under ∆9-THC, cannabis users showed brain activity patterns intermediate between those in non-users under placebo (control group), and non-users under ∆9-THC (acute effect) and cannabis users under placebo (residual effect). In non-users, the more severe the ∆9-THC-induced psychotomimetic symptoms and cognitive impairments, the more pronounced was the neurophysiological alteration (all P≤0.036). Discussion: Previous modest cannabis use blunts the acute behavioral and neurophysiological effects of ∆9-THC, which are more marked in people who have never used cannabis. 
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Background: Weight gain is an extremely common problem in schizophrenia patients and is associated with morbidity and mortality. We conducted a Cochrane meta-analysis to determine the effects of pharmacological interventions aimed at reduction or prevention of weight gain in schizophrenia. Methods: We searched the Cochrane Schizophrenia Group's Trials Register that is based on regular searches of CINAHL, BIOSIS, AMED, EMBASE, PubMed, MEDLINE, PsycINFO, and registries of clinical trials. There is no language, date, document type, or publication status limitations for inclusion of records in the register. We also searched reference sections within relevant papers, hand searched key journals, and contacted the first author of each relevant study and other experts to collect further information. We included all double blind randomized controlled trials examining any adjunctive pharmacological intervention for weight loss (treatment) or weight maintenance (prevention) in patients with schizophrenia or schizophrenia-like illnesses. We reliably selected, quality assessed and extracted data from studies. As endpoint and change data were combined in the analysis, mean differences (MD) of the change from baseline were calculated. The primary outcome measure was weight loss. Results: Forty-four randomized controlled trials met the inclusion criteria for this review. Ten studies examined prevention of weight gain while on antipsychotics. Reboxetine may be slightly effective in preventing weight gain (Weight: MD -2.09 kg, 95% CI -3.12 to -1.05; participants = 111; studies = 3; BMI: MD -0.70, 95% CI -1.03 to -0.36; participants = 111; studies = 3) and but the quality of evidence is low as the studies are small and have all been conducted by the same group. We are uncertain about the other agents used in a preventive role because the quality of evidence is very low. Thirty-four studies examined reduction of weight gain with pharmacological interventions. Metformin is effective in bringing about modest weight loss (MD -3.45 kg, 95% CI -4.92 to -1.98 kg; participants = 569; studies = 8; BMI: MD -1.32 kg/m2, 95% CI -1.84 to -0.81 kg/m2; participants = 606; studies = 9). This effect is probably stronger in first episode psychosis (FEP) patients (Weight: MD -5.18 kg, 95% CI -6.22 to -4.14 kg; participants = 214; studies = 3; BMI: MD -1.87 kg/m2, 95% CI -2.19 to -1.56 kg/m2; participants = 214; studies = 3) compared to chronic patients (Weight: MD -2.0 kg, 95% CI -3.0 to -1.0 kg; participants = 355; studies = 5; BMI: MD -0.73 kg/m2, 95% CI -1.04 to -0.42 kg/m2; participants = 392; studies = 6). Metformin probably decreases fasting insulin levels and insulin resistance as well. The frequency of adverse effects did not differ between metformin and placebo groups. Other agents that may reduce weight include aripiprazole, topiramate, H2 antagonists such as nizatidine, and sibutramine but the quality of the evidence is low or very low making the effects uncertain. Importantly, none of the adjunctive treatment strategies result in higher dropout rates. Other than higher reports of anxiety with aripiprazole, none of the adjunctive treatment strategies appear to result in worsening of mental status. Discussion: Accumulating evidence supports the safe use of pharmacological interventions to achieve modest weight loss. Reboxetine may be slightly effective in preventing weight gain while metformin has the most evidence for use as treatment of weight gain in schizophrenia. The small number of studies, small sample size, and short study duration limits interpretation for other agents. Future studies that are adequately powered, with longer treatment duration, will be needed in evaluating the efficacy and safety of interventions for managing weight gain further. 
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